Lung cancer after neoadjuvant therapy
Jump to navigation
Jump to search
Creating Lung cancer after neoadjuvant therapy is assessed using a consensus protocol.[1]
See also
References
- ↑ Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y (May 2020). "IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy". J Thorac Oncol 15 (5): 709–740. doi:10.1016/j.jtho.2020.01.005. PMC 8173999. PMID 32004713. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173999/.